The Official Website of the Long-Term Investor
Results 71 - 80 of 757 : Previous 4 5 6 7 8 9 10 11 12 Next
The Calm Before the Revenue Storm?
Gilead's growth is decelerating, but it still has a few tricks up its sleeve.
Is ViroPharma's Growth for Real?
These two simple metrics can save you a lot of pain.
Debt Supercycle: Are These Leveraged Companies in Trouble?
Big money managers appear to be concerned about the debt levels at these companies. Are any of them in your portfolio?
Check out the cash king margin
Why the Street Should Love Gilead Sciences' Earnings
All cash flow is not created equal.
The 8 Highest Potential Returns in Biotechnology
What the numbers tell us.
Here's 1 Reason Gilead Sciences Looks Weak
Keep your eye on margins.
Gilead pumps up the pipeline.
5-Star ETFs Poised to Pop: iShares Nasdaq Biotechnology
Market-trouncing returns could be written in this 5-Star.
This Just In: Upgrades and Downgrades
Imperial Capital banishes Dendreon.
BATS data provided in real-time. NYSE, NASDAQ and AMEX data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates and Analyst Ratings provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK